Abstract P1-03-02: Preclinical efficacy of a novel and potent inhibitor of the MDM2-p53 axis AMG 232 in ER+ breast cancer modelPK De, B Leyland-Jones, Tyler Jepperson et al.|Cancer Research|2018Cited by 0